The pharmaceutical industry’s story has been defined by two main pillars: pills and proteins. However, a groundbreaking third platform is emerging—genetic treatments.
Rachel Haurwitz, CEO of Caribou Biosciences, highlights how nucleic acids, RNA strands, replacement DNA sequences, and advanced enzymes are shaping this transformative wave in medicine. These treatments include innovations like specialized viral vectors and entire cell-based therapies, offering new possibilities for addressing complex diseases.